Logo image of APTX

APTINYX INC (APTX) Stock Fundamental Analysis

NASDAQ:APTX - Nasdaq - US03836N1037 - Common Stock - Currency: USD

0.061  -0.04 (-39%)

After market: 0.074 +0.01 (+21.31%)

Fundamental Rating

2

APTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. Both the profitability and financial health of APTX have multiple concerns. APTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APTX had negative earnings in the past year.
In the past year APTX has reported a negative cash flow from operations.
In the past 5 years APTX always reported negative net income.
APTX had a negative operating cash flow in each of the past 5 years.
APTX Yearly Net Income VS EBIT VS OCF VS FCFAPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The profitability ratios for APTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APTX Yearly ROA, ROE, ROICAPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APTX Yearly Profit, Operating, Gross MarginsAPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

APTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
APTX has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, APTX has a worse debt to assets ratio.
APTX Yearly Shares OutstandingAPTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
APTX Yearly Total Debt VS Total AssetsAPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.38, we must say that APTX is in the distress zone and has some risk of bankruptcy.
APTX has a worse Altman-Z score (-9.38) than 75.87% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that APTX is somewhat dependend on debt financing.
APTX has a Debt to Equity ratio of 0.58. This is in the lower half of the industry: APTX underperforms 75.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -9.38
ROIC/WACCN/A
WACC6.92%
APTX Yearly LT Debt VS Equity VS FCFAPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

APTX has a Current Ratio of 10.18. This indicates that APTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 10.18, APTX is doing good in the industry, outperforming 75.71% of the companies in the same industry.
APTX has a Quick Ratio of 10.18. This indicates that APTX is financially healthy and has no problem in meeting its short term obligations.
APTX has a better Quick ratio (10.18) than 75.87% of its industry peers.
Industry RankSector Rank
Current Ratio 10.18
Quick Ratio 10.18
APTX Yearly Current Assets VS Current LiabilitesAPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

APTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.51%, which is quite good.
APTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.93%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, APTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.76% on average per year.
Based on estimates for the next years, APTX will show a very strong growth in Revenue. The Revenue will grow by 204.67% on average per year.
EPS Next Y50.06%
EPS Next 2Y23.79%
EPS Next 3Y15.29%
EPS Next 5Y8.76%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y204.67%

3.3 Evolution

APTX Yearly Revenue VS EstimatesAPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2027 2028 2029 2030 100M 200M 300M
APTX Yearly EPS VS EstimatesAPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APTX Price Earnings VS Forward Price EarningsAPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APTX Per share dataAPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

APTX's earnings are expected to grow with 15.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.79%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

APTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTINYX INC

NASDAQ:APTX (5/18/2023, 8:22:26 PM)

After market: 0.074 +0.01 (+21.31%)

0.061

-0.04 (-39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-17 2023-05-17/amc
Earnings (Next)08-02 2023-08-02/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners7.7%
Ins Owner Change0%
Market Cap4.13M
Analysts47.5
Price Target0.51 (736.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.38%
Min EPS beat(2)6.44%
Max EPS beat(2)8.33%
EPS beat(4)4
Avg EPS beat(4)7.6%
Min EPS beat(4)6.4%
Max EPS beat(4)9.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.82%
EPS NY rev (1m)0%
EPS NY rev (3m)35.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.11
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.18
Quick Ratio 10.18
Altman-Z -9.38
F-ScoreN/A
WACC6.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.93%
EPS Next Y50.06%
EPS Next 2Y23.79%
EPS Next 3Y15.29%
EPS Next 5Y8.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y204.67%
EBIT growth 1Y16.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.82%
EBIT Next 3Y78.71%
EBIT Next 5Y60%
FCF growth 1Y5.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.9%
OCF growth 3YN/A
OCF growth 5YN/A